![Wei Cao](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Wei Cao
Directeur Général chez
GRACELL BIOTECHNOLOGIES INC.
Profil
Wei Cao is the founder of Gracell Biotechnologies (Shanghai) Co., Ltd. (founded in 2017) and Gracell Biotechnologies, Inc. (founded in 2017).
He is currently the Chief Executive Officer at Gracell Biotechnologies (HK) Ltd., Gracell Biopharmaceuticals, Inc., Suzhou Gracell Biotechnologies Co., Ltd., and Zephyrm Bioscience Ltd. (as an Independent Non-Executive Director starting in 2024).
Dr. Cao previously worked as a Director at AbelZeta Pharma, Inc. from 2010 to 2016 and as the President, Chief Operating Officer & Director at Cellular Biomedicine Group Ltd. from 2010 to 2013.
He holds a doctorate degree from Medical College of Virginia and Harvard Medical School, and an undergraduate degree from Zhongshan Hospital Fudan University.
Postes actifs de Wei Cao
| Sociétés | Poste | Début |
|---|---|---|
| GRACELL BIOTECHNOLOGIES INC. | Directeur Général | 01/05/2017 |
Gracell Biotechnologies (Shanghai) Co., Ltd.
 Gracell Biotechnologies (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates a clinical-stage biopharmaceutical company which discovers and develops cellular therapeutics for the patients suffering with cancer | Fondateur | 21/05/2017 |
Gracell Biotechnologies (HK) Ltd. | Directeur Général | - |
Gracell Biopharmaceuticals, Inc.
 Gracell Biopharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Part of AstraZeneca PLC, Gracell Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in cell therapies for cancer and autoimmune diseases. The company is based in Dover, DE. The company develops next-generation CAR-T therapies that address challenges of conventional treatments, such as long manufacturing times, immune rejection, and limited efficacy against solid tumors. Its proprietary technology platforms include FasTCAR™, which enables rapid, next-day manufacturing of autologous CAR-T cells; TruUCAR™, an off-the-shelf allogeneic CAR-T platform using gene editing to reduce graft-versus-host disease and immune rejection; and SMART CART™, designed to overcome barriers in solid tumor treatment. Gracell advances a pipeline of dual-targeted CAR-T candidates, such as GC012F targeting BCMA and CD19, currently in clinical trials for multiple myeloma and refractory systemic lupus erythematosus. The company’s manufacturing capabilities include fully closed systems and collaborations to ensure high-quality, scalable production. The CEO of the company is Wei Cao. | Directeur Général | - |
Suzhou Gracell Biotechnologies Co., Ltd.
 Suzhou Gracell Biotechnologies Co., Ltd. Pharmaceuticals: MajorHealth Technology Manufactures cancer cellular medicines | Directeur Général | - |
Anciens postes connus de Wei Cao
| Sociétés | Poste | Fin |
|---|---|---|
| CELLULAR BIOMEDICINE GROUP, INC. | Directeur Général | 06/02/2016 |
Cellular Biomedicine Group Ltd. | President | 01/02/2013 |
Formation de Wei Cao
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
19
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Medical College of Virginia
 Medical College of Virginia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zhongshan Hospital Fudan University
 Zhongshan Hospital Fudan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AbelZeta Pharma, Inc.
 AbelZeta Pharma, Inc. BiotechnologyHealth Technology Develops cell therapies to cure cancer and inflammatory & immunological diseases | Health Technology |
Cellular Biomedicine Group Ltd. | |
Gracell Biotechnologies (Shanghai) Co., Ltd.
Gracell Biotechnologies (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates a clinical-stage biopharmaceutical company which discovers and develops cellular therapeutics for the patients suffering with cancer | Health Technology |
Gracell Biotechnologies, Inc.
 Gracell Biotechnologies, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cell and gene therapy for the treatment of cancer and autoimmune diseases | Health Technology |
Gracell Biotechnologies (HK) Ltd. | |
Gracell Biopharmaceuticals, Inc.
Gracell Biopharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Part of AstraZeneca PLC, Gracell Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in cell therapies for cancer and autoimmune diseases. The company is based in Dover, DE. The company develops next-generation CAR-T therapies that address challenges of conventional treatments, such as long manufacturing times, immune rejection, and limited efficacy against solid tumors. Its proprietary technology platforms include FasTCAR™, which enables rapid, next-day manufacturing of autologous CAR-T cells; TruUCAR™, an off-the-shelf allogeneic CAR-T platform using gene editing to reduce graft-versus-host disease and immune rejection; and SMART CART™, designed to overcome barriers in solid tumor treatment. Gracell advances a pipeline of dual-targeted CAR-T candidates, such as GC012F targeting BCMA and CD19, currently in clinical trials for multiple myeloma and refractory systemic lupus erythematosus. The company’s manufacturing capabilities include fully closed systems and collaborations to ensure high-quality, scalable production. The CEO of the company is Wei Cao. | Health Services |
Suzhou Gracell Biotechnologies Co., Ltd.
Suzhou Gracell Biotechnologies Co., Ltd. Pharmaceuticals: MajorHealth Technology Manufactures cancer cellular medicines | Health Technology |
